Randomized controlled trial of twice-a-day administration of natural interferon Î² for chronic hepatitis C

Yoshioka, Kentaro; Yano, Motoyoshi; Hirofuji, Hideo; Arao, Motohiro; Kusakabe, Atsuhiko; Sameshima, Yoichi; Kuriki, Junsuke; Kurokawa, Susumu; Murase, Kohei; Ishikawa, Tetsuya; Kakumu, Shinichi

doi:10.1016/s1386-6346(00)00080-2

Cited by 9 publications

(10 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Japan, the use of IFN-β aiming to enhance viral clearance in the early phase of treatment when administering induction therapy has been reported [20][21][22][23] . A characteristic of IFN-β is that the administration in equally divided doses in the morning and evening increases the HCV-RNA reduction rate [11][12][13][14][15] , as we first reported (in Japanese) in 1995 [24] .…”

Section: Discussionmentioning

confidence: 99%

Twenty four-week peginterferon plus ribavirin after interferon-β induction for genotype 1b chronic hepatitis C

Okushin

Morii²,

Uesaka³

et al. 2010

WJH

View full text Add to dashboard Cite

AIM:To investigate the possibility of shortening the duration of peginterferon (Peg-IFN) plus ribavirin (RBV) combination therapy by incorporating interferon-β (IFN-β) induction therapy. METHODS:A one treatment arm, cohort prospective study was conducted on seventy one patients. The patients were Japanese adults with genotype 1b chronic hepatitis C, HCV-RNA levels of ≥ 5.0 Log IU/mL or 100 KIU/mL, and platelet counts of ≥ 90 000/µL. The treatment regimen consisted of a 2 wk course of twicedaily administration of IFN-β followed by 24 wk Peg-IFN plus RBV combination therapy. We prolonged the duration of the Peg-IFN plus RBV therapy to 48 wk if the patient requested it. RESULTS:The patients, including 44% males, were characterized by an median age of 63 years (range: 32-78 years), an median platelet count of 13.9 (range: 9.1-30.6) × 10 4 /µL, 62% IFN-naïve, and median HCV-RNA of 6.1 (range: 5.1-7.2) Log IU/mL. The sustained virologic response (SVR) rates were 34% (Peg-IFN: 1-24 wk, n = 61, 95% confidence interval (CI): 24%-47%) and 55% (Peg-IFN: 20-24 wk, n = 31, 95% CI: 38%-71%, P < 0.001; vs Peg-IFN: 1-19 wk). The SVR rate when the administration was discontinued early was 13% (Peg-IFN: 1-19 wk, n = 30, 95% CI: 5%-30%), and that when the administration was prolonged was 50% (Peg-IFN: 25-48 wk, n = 10, 95% CI: 24%-76%, P < 0.05; vs Peg-IFN: 1-19 wk). In the patients who received 20-24 wk of Peg-IFN plus RBV, only the higher platelet count (≥ 130 000/µL) was significantly correlated with the SVR (odds ratio:11.680, 95% CI: 2.3064-79.474, P = 0.0024). In 45% (14/31) of the patients with a higher platelet count (≥ 130 000/µL) before therapy, the HCV-RNA level decreased to below 3.3 Log IU/mL at the completion of IFN-β, and their SVR rate was 93% (13/14) after 20-24 wk administration of Peg-IFN plus RBV. CONCLUSION:These results suggest the possibilities of shortening the duration of Peg-IFN plus RBV combination therapy by actively reducing HCV-RNA levels using the IFN-β induction regimen. Okushin H, Morii K, Uesaka K, Yuasa S. Twenty four-week peginterferon plus ribavirin after interferon-β induction for genotype 1b chronic hepatitis C.

show abstract

Section: Discussionmentioning

confidence: 99%

Twenty four-week peginterferon plus ribavirin after interferon-β induction for genotype 1b chronic hepatitis C

Okushin

Morii²,

Uesaka³

et al. 2010

WJH

View full text Add to dashboard Cite

show abstract

“…In many reports to date on IFN‐β induction therapy in clinical practice, HCV RNA negativization or a steep slope of viral decline was described in the initial stage of treatment, but a pronounced increase in the SVR rate was not obtained 20,21 …”

Section: Discussionmentioning

confidence: 99%

“…In many reports to date on IFN-b induction therapy in clinical practice, HCV RNA negativization or a steep slope of viral decline was described in the initial stage of treatment, but a pronounced increase in the SVR rate was not obtained. 20,21 When the viral negativization was accelerated by the IFN-b induction, LVR patients, for whom PEG IFN-a-2b/RBV combination therapy for 72 weeks is usually required, would be regarded as having EVR and undergo 48-week PEG IFN-a-2b/RBV combination therapy. A long-standing clinical concern was that the use of IFN-b in promoting rapid viral clearance might result in an increase in the proportion of relapses because LVR patients requiring 72-week PEG IFN-a-2b plus RBV combination therapy would be judged as EVR patients and treated for only 48 weeks.…”

Section: N Japan Most Patients With Chc Have Genotype 1bmentioning

confidence: 99%

Efficacy of the regimen using twice‐daily β‐interferon followed by the standard of care for chronic hepatitis C genotype 1b with high viral load

Ishikawa

Kubota

Abé

et al. 2012

Hepatology Research

View full text Add to dashboard Cite

show abstract

“…However, twice‐daily treatment induced more adverse reactions, including thrombocytopenia and renal toxicity. Therefore, it is difficult to continue twice‐daily administration for a long period of time, and no significant increase in SVR has been achieved with twice‐daily treatment compared to once‐daily treatment 21–23 . Given that ribavirin combination therapy with more potent induction therapy could achieve earlier viral clearance and could improve the SVR, we decided to give IFN‐β twice daily for 2 weeks, while taking safety into account.…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, it is difficult to continue twice-daily administration for a long period of time, and no significant increase in SVR has been achieved with twice-daily treatment compared to once-daily treatment. [21][22][23] Given that ribavirin combination therapy with more potent induction therapy could achieve earlier viral clearance and could improve the SVR, we decided to give IFN-b twice daily for 2 weeks, while taking safety into account. As expected, the HCV-RNA-negative rate with twice-daily treatment (40%) was higher than that for once-daily treatment (23%); while the negative rate for twice-daily treatment was higher, there was no marked difference in the cumulative HCV-RNA-negative rate or the SVR compared to once-daily treatment.…”

Section: Discussionmentioning

confidence: 99%

Potent induction therapy with interferon and ribavirin combination therapy does not achieve a higher sustained virological response rate in chronic hepatitis C with genotype 1b and high hepatitis C virus RNA level

Enomoto

Tamai

Oka

et al. 2007

Hepatology Research

View full text Add to dashboard Cite

show abstract

Randomized controlled trial of twice-a-day administration of natural interferon Î² for chronic hepatitis C

Cited by 9 publications

References 20 publications

Twenty four-week peginterferon plus ribavirin after interferon-β induction for genotype 1b chronic hepatitis C

Twenty four-week peginterferon plus ribavirin after interferon-β induction for genotype 1b chronic hepatitis C

Efficacy of the regimen using twice‐daily β‐interferon followed by the standard of care for chronic hepatitis C genotype 1b with high viral load

Potent induction therapy with interferon and ribavirin combination therapy does not achieve a higher sustained virological response rate in chronic hepatitis C with genotype 1b and high hepatitis C virus RNA level

Contact Info

Product

Resources

About